XML 54 R43.htm IDEA: XBRL DOCUMENT
v3.25.1

Product and Geographic Information - Schedule of Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2025 | Mar. 31, 2024
Revenue from External Customer [Line Items] |  |
Revenues | $ 1,513 | $ 1,622
Nexplanon/Implanon NXT |  |
Revenue from External Customer [Line Items] |  |
Revenues | 248 | 220
Follistim AQ |  |
Revenue from External Customer [Line Items] |  |
Revenues | 69 | 46
NuvaRing |  |
Revenue from External Customer [Line Items] |  |
Revenues | 22 | 38
Ganirelix Acetate Injection |  |
Revenue from External Customer [Line Items] |  |
Revenues | 27 | 29
Marvelon/Mercilon |  |
Revenue from External Customer [Line Items] |  |
Revenues | 39 | 33
Jada |  |
Revenue from External Customer [Line Items] |  |
Revenues | 15 | 13
Other Women's Health |  |
Revenue from External Customer [Line Items] |  |
Revenues | 43 | 43
Renflexis |  |
Revenue from External Customer [Line Items] |  |
Revenues | 57 | 69
Hadlima |  |
Revenue from External Customer [Line Items] |  |
Revenues | 47 | 30
Ontruzant |  |
Revenue from External Customer [Line Items] |  |
Revenues | 18 | 39
Brenzys |  |
Revenue from External Customer [Line Items] |  |
Revenues | 14 | 24
Aybintio |  |
Revenue from External Customer [Line Items] |  |
Revenues | 5 | 8
Atozet |  |
Revenue from External Customer [Line Items] |  |
Revenues | 77 | 132
Zetia |  |
Revenue from External Customer [Line Items] |  |
Revenues | 85 | 84
Cozaar/Hyzaar |  |
Revenue from External Customer [Line Items] |  |
Revenues | 55 | 67
Vytorin |  |
Revenue from External Customer [Line Items] |  |
Revenues | 23 | 28
Rosuzet |  |
Revenue from External Customer [Line Items] |  |
Revenues | 4 | 16
Other Cardiovascular |  |
Revenue from External Customer [Line Items] |  |
Revenues | 30 | 38
Singulair |  |
Revenue from External Customer [Line Items] |  |
Revenues | 74 | 98
Nasonex |  |
Revenue from External Customer [Line Items] |  |
Revenues | 72 | 77
Dulera |  |
Revenue from External Customer [Line Items] |  |
Revenues | 43 | 56
Clarinex |  |
Revenue from External Customer [Line Items] |  |
Revenues | 34 | 37
Other Respiratory |  |
Revenue from External Customer [Line Items] |  |
Revenues | 13 | 9
Arcoxia |  |
Revenue from External Customer [Line Items] |  |
Revenues | 62 | 75
Fosamax |  |
Revenue from External Customer [Line Items] |  |
Revenues | 33 | 40
Diprospan |  |
Revenue from External Customer [Line Items] |  |
Revenues | 30 | 29
Vtama |  |
Revenue from External Customer [Line Items] |  |
Revenues | 24 | 0
Other Non-Opiod Pain, Bone and Dermatology |  |
Revenue from External Customer [Line Items] |  |
Revenues | 68 | 72
Propecia |  |
Revenue from External Customer [Line Items] |  |
Revenues | 26 | 23
Emgality/Rayvow |  |
Revenue from External Customer [Line Items] |  |
Revenues | 32 | 10
Proscar |  |
Revenue from External Customer [Line Items] |  |
Revenues | 24 | 26
Other |  |
Revenue from External Customer [Line Items] |  |
Revenues | 78 | 84
Other |  |
Revenue from External Customer [Line Items] |  |
Revenues | 22 | 29
U.S. |  |
Revenue from External Customer [Line Items] |  |
Revenues | 412 | 371
U.S. | Nexplanon/Implanon NXT |  |
Revenue from External Customer [Line Items] |  |
Revenues | 176 | 153
U.S. | Follistim AQ |  |
Revenue from External Customer [Line Items] |  |
Revenues | 35 | 11
U.S. | NuvaRing |  |
Revenue from External Customer [Line Items] |  |
Revenues | 6 | 16
U.S. | Ganirelix Acetate Injection |  |
Revenue from External Customer [Line Items] |  |
Revenues | 5 | 6
U.S. | Marvelon/Mercilon |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Jada |  |
Revenue from External Customer [Line Items] |  |
Revenues | 15 | 13
U.S. | Other Women's Health |  |
Revenue from External Customer [Line Items] |  |
Revenues | 15 | 15
U.S. | Renflexis |  |
Revenue from External Customer [Line Items] |  |
Revenues | 44 | 55
U.S. | Hadlima |  |
Revenue from External Customer [Line Items] |  |
Revenues | 33 | 22
U.S. | Ontruzant |  |
Revenue from External Customer [Line Items] |  |
Revenues | 4 | 8
U.S. | Brenzys |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Aybintio |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Atozet |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Zetia |  |
Revenue from External Customer [Line Items] |  |
Revenues | 1 | 2
U.S. | Cozaar/Hyzaar |  |
Revenue from External Customer [Line Items] |  |
Revenues | 2 | 3
U.S. | Vytorin |  |
Revenue from External Customer [Line Items] |  |
Revenues | 1 | 1
U.S. | Rosuzet |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Other Cardiovascular |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Singulair |  |
Revenue from External Customer [Line Items] |  |
Revenues | 2 | 2
U.S. | Nasonex |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Dulera |  |
Revenue from External Customer [Line Items] |  |
Revenues | 34 | 43
U.S. | Clarinex |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 1
U.S. | Other Respiratory |  |
Revenue from External Customer [Line Items] |  |
Revenues | 10 | 7
U.S. | Arcoxia |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Fosamax |  |
Revenue from External Customer [Line Items] |  |
Revenues | 1 | 1
U.S. | Diprospan |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Vtama |  |
Revenue from External Customer [Line Items] |  |
Revenues | 20 | 0
U.S. | Other Non-Opiod Pain, Bone and Dermatology |  |
Revenue from External Customer [Line Items] |  |
Revenues | 4 | 5
U.S. | Propecia |  |
Revenue from External Customer [Line Items] |  |
Revenues | 1 | 2
U.S. | Emgality/Rayvow |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Proscar |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
U.S. | Other |  |
Revenue from External Customer [Line Items] |  |
Revenues | 3 | 5
U.S. | Other |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
Int’l |  |
Revenue from External Customer [Line Items] |  |
Revenues | 1,101 | 1,251
Int’l | Nexplanon/Implanon NXT |  |
Revenue from External Customer [Line Items] |  |
Revenues | 72 | 67
Int’l | Follistim AQ |  |
Revenue from External Customer [Line Items] |  |
Revenues | 34 | 35
Int’l | NuvaRing |  |
Revenue from External Customer [Line Items] |  |
Revenues | 16 | 22
Int’l | Ganirelix Acetate Injection |  |
Revenue from External Customer [Line Items] |  |
Revenues | 23 | 23
Int’l | Marvelon/Mercilon |  |
Revenue from External Customer [Line Items] |  |
Revenues | 39 | 33
Int’l | Jada |  |
Revenue from External Customer [Line Items] |  |
Revenues | 0 | 0
Int’l | Other Women's Health |  |
Revenue from External Customer [Line Items] |  |
Revenues | 27 | 28
Int’l | Renflexis |  |
Revenue from External Customer [Line Items] |  |
Revenues | 12 | 14
Int’l | Hadlima |  |
Revenue from External Customer [Line Items] |  |
Revenues | 14 | 8
Int’l | Ontruzant |  |
Revenue from External Customer [Line Items] |  |
Revenues | 14 | 31
Int’l | Brenzys |  |
Revenue from External Customer [Line Items] |  |
Revenues | 14 | 24
Int’l | Aybintio |  |
Revenue from External Customer [Line Items] |  |
Revenues | 5 | 8
Int’l | Atozet |  |
Revenue from External Customer [Line Items] |  |
Revenues | 77 | 132
Int’l | Zetia |  |
Revenue from External Customer [Line Items] |  |
Revenues | 84 | 82
Int’l | Cozaar/Hyzaar |  |
Revenue from External Customer [Line Items] |  |
Revenues | 53 | 65
Int’l | Vytorin |  |
Revenue from External Customer [Line Items] |  |
Revenues | 22 | 27
Int’l | Rosuzet |  |
Revenue from External Customer [Line Items] |  |
Revenues | 4 | 16
Int’l | Other Cardiovascular |  |
Revenue from External Customer [Line Items] |  |
Revenues | 30 | 37
Int’l | Singulair |  |
Revenue from External Customer [Line Items] |  |
Revenues | 72 | 95
Int’l | Nasonex |  |
Revenue from External Customer [Line Items] |  |
Revenues | 71 | 77
Int’l | Dulera |  |
Revenue from External Customer [Line Items] |  |
Revenues | 10 | 13
Int’l | Clarinex |  |
Revenue from External Customer [Line Items] |  |
Revenues | 34 | 36
Int’l | Other Respiratory |  |
Revenue from External Customer [Line Items] |  |
Revenues | 3 | 3
Int’l | Arcoxia |  |
Revenue from External Customer [Line Items] |  |
Revenues | 62 | 75
Int’l | Fosamax |  |
Revenue from External Customer [Line Items] |  |
Revenues | 32 | 38
Int’l | Diprospan |  |
Revenue from External Customer [Line Items] |  |
Revenues | 30 | 29
Int’l | Vtama |  |
Revenue from External Customer [Line Items] |  |
Revenues | 4 | 0
Int’l | Other Non-Opiod Pain, Bone and Dermatology |  |
Revenue from External Customer [Line Items] |  |
Revenues | 65 | 68
Int’l | Propecia |  |
Revenue from External Customer [Line Items] |  |
Revenues | 24 | 21
Int’l | Emgality/Rayvow |  |
Revenue from External Customer [Line Items] |  |
Revenues | 32 | 10
Int’l | Proscar |  |
Revenue from External Customer [Line Items] |  |
Revenues | 24 | 26
Int’l | Other |  |
Revenue from External Customer [Line Items] |  |
Revenues | 76 | 79
Int’l | Other |  |
Revenue from External Customer [Line Items] |  |
Revenues | $ 22 | $ 29

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_NexplanonImplanonNXTMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_FollistimAQMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_NuvaRingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_GanirelixAcetateInjectionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_MarvelonMercilonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_JadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_OtherWomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_RenflexisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_HadlimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_OntruzantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_BrenzysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_AybintioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_RosuzetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_OtherCardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_DuleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_ClarinexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_OtherRespiratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_FosamaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_DiprospanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_VtamaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_OtherNonOpiodPainBoneAndDermatologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_PropeciaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_EmgalityRavvowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_ProscarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_OtherSundryEstablishedBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ogn_OtherSundryProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |